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Los Angeles, California
Regenerative therapy for myocardial infarction (MI) seeks
to regrow healthy heart muscle that, once lost, has tradi-
tionally been assumed to be gone forever. After a decade of
stuttering progress (1), we now have reason to believe that
therapeutic regeneration is indeed possible in human beings.
In the CADUCEUS (Cardiosphere-Derived Autologous
Stem Cells to Reverse Ventricular Dysfunction) trial (2),
post-MI patients treated with cardiosphere-derived cells
regrew substantial amounts of healthy heart muscle, whereas
control subjects did not. The newly grown myocardium was
viable by contrast-enhanced magnetic resonance imaging
and was functional as gauged by magnetic resonance imag-
ing tagging and regional systolic thickening. As with any
phase 1 study, enthusiasm must be tempered by the small
numbers involved; larger studies will be required to reach
definitive conclusions. Nevertheless, we now know that ther-
apeutic regeneration is possible, but we do not yet know how
to achieve optimal effects in any given patient population.
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The default approach to regeneration is via stem cell
therapy, motivated by the simple notion that injected cells
engraft, proliferate, differentiate, and repopulate the injured
heart. This guiding principle has turned out to be mis-
guided: mounting evidence now indicates that most of the
beneficial effects of transplanted cells are indirect (3,4), at
least for nonpluripotent cells. Some (but not all) clinically
applied cell types are rich biological factories, secreting
soluble factors that may promote angiogenesis, inhibit
programmed cell death, recruit endogenous progenitor cells,
or coax surviving heart cells to proliferate (5). In this issue of
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the paracrine hypothesis: Are cells needed for regenerative
therapy, or will secreted factors suffice?
The experimental approach is straightforward: Rats with
acute MI were injected with mesenchymal stem cells
(MSC), normoxic paracrine media (PM), or hypoxic PM in
the MI border zone. Before delving into details, a note of
reassurance to nonelectrophysiologists: The endpoints may
seem arcane, but the salutary effects are all consistent with
(and likely attributable to) increased tissue viability. The
investigators injected saline (sham), PM collected from 1 
06 MSC after 12 h in culture under either normoxic or
hypoxic conditions, or cells themselves (1  106 MSC).
Rats were monitored for 11 days for arrhythmias; hemody-
namic, electrophysiological, and biochemical studies were
performed at the end of the experimental protocol. Over the
brief follow-up period, hypoxic PM–treated rats exhibited a
reduction in sudden cardiac death (13% in the hypoxic PM
group vs. 57% in the sham group), but little benefit was
apparent in MSC-treated or normoxic PM–treated rats. Ex
vivo burst pacing confirmed a decreased ability to induce
ventricular tachycardia in hypoxic PM animals versus nor-
moxic PM, MSC, and sham groups. Whole-heart optical
mapping revealed restoration of conduction velocity and
decreased triggered activity in the MI border zone, further
supporting the “antiarrhythmic” effect of hypoxic PM in the
present MI model.
Various morphological and biochemical assays add tex-
ture to the phenotypic characterization. The prevalence of
apoptotic (deoxyuride-5=-triphosphate biotin nick end la-
beling ) myocytes was decreased by 50% in hypoxic
PM–treated hearts versus sham-treated ones. Moreover,
whereas decreased fibrosis was evident in hypoxic PM–
treated rats, no changes were observed in normoxic PM– or
MSC-treated animals. In agreement with the changes in
conduction velocity by optical mapping, expression of con-
nexin 43 was increased in hypoxic PM–treated hearts.
Decreased levels of calcium handling proteins (L-type Ca2
channel, sarcoplasmic/endoplasmic reticulum calcium aden-
osine triphosphatase 2a, calreticulin, calmodulin) were seen
in sham-treated rats, consistent with heart failure; such
changes were blunted in hypoxic PM–treated hearts. These
effects presumably underlie the improvement in border zone
conduction velocity, which would tend to suppress re-
entrant arrhythmias, and a concomitant decrease in after-
depolarizations associated with triggered arrhythmias (7).
Proteomic analyses showed increased expression of growth
factors (basic fibroblast growth factor, insulinlike growth
factor 1, hepatocyte growth factor) in hypoxic PM versus
normoxic PM, but the specific factors responsible for the
beneficial effects have yet to be pinpointed. So, in summary,
hypoxic PM is best, and in fact is so effective that its effects
rival those described in the most exuberantly positive pre-
clinical studies of cell therapy (1).
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physiological effects of cell therapy in a rodent model of
acute MI, the following limitations need to be taken into
consideration:
• Although increased levels of growth factors such as
basic fibroblast growth factor, insulinlike growth
factor-1, and hepatocyte growth factor were demon-
strated in hypoxic PM, there was no quantification of
the total concentration of the media (or its individual
constituents) administered in vivo. Evaluation of the
concentration and dose/response of the individual
factors would be crucial prior to translating this con-
cept to pre-clinical and clinical studies.
• The investigators emphasize the marked improvement
seen with hypoxic PM over normoxic PM and un-
stressed MSC, but there was no comparison with
hypoxic MSC. Mechanisms that come into play only
when transplanted cells interact with host myocardium
will be lost if there is sole reliance on secreted factors.
Indeed, there is emerging evidence that such contact-
dependent mechanisms may play a crucial role in the
overall benefit of cell transplantation (8).
• Whereas the present discussion is focused on pro-
teomically identifiable growth factors as key players in
the observed physiological changes, other factors such
as exosomal micro ribonucleic acids may also play an
important role (4,9).
• Whereas a significant effect was seen with hypoxic PM
during the 11-day period, longer studies would be
desirable to know if the beneficial effects persist over
time. In this regard, a sustained-release formulation of
growth factors and/or micro ribonucleic acids may
have a more durable beneficial effect.
• The model is one of intervention in the acute MI
setting. As such, it is unclear whether the observed
benefits of hypoxic PM are due to regeneration or to
tissue preservation. Longer-term models of reperfused
MI will be required to draw this clinically relevant
distinction.
Whether triggered by secreted factors or by allogeneic
cells, indirect mechanisms of regeneration may turn out to
be safer, and more durable, than direct differentiation of
transplanted exogenous cells. Coaxing nature to regrow
myocardium endogenously maximizes the chances that cell-
cell electrical connections will be robust and correctly
aligned and that the newly grown heart tissue will be
functional over time. Here, the experience with skeletal
myoblasts provides a relevant parable: Exogenous cells thatengraft and remain electrically uncoupled to the host myo-
cardium are proarrhythmic, both experimentally (10) and in
phase-1 clinical trials (11). In contrast, no increase in
arrhythmias has been encountered with bone marrow–
derived cells (12), which do not survive for long in the host
myocardium. Endogenous regeneration, by distilled soluble
factors or by transplanted cells, could potentially result in a
more homogeneous, less-arrhythmogenic substrate (13).
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